<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832555</url>
  </required_header>
  <id_info>
    <org_study_id>NEVER</org_study_id>
    <nct_id>NCT04832555</nct_id>
  </id_info>
  <brief_title>Non Elective Vulnerable Elderly Radiotherapy</brief_title>
  <acronym>NEVER</acronym>
  <official_title>Non Elective Vulnerable Elderly Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero Universitaria Policlinico Modena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero Universitaria Policlinico Modena</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether patients defined &quot;non-fit for curative non-surgical radio-chemotherapy&quot;&#xD;
      and therefore treated with RT alone addressed only to non-elective sites of disease, could&#xD;
      obtain a non-inferior loco-regional control compared to similar historical cohorts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard approach for head and neck malignancies cannot be considered the gold&#xD;
      standard for elderly patients, except in carefully selected cases. Given the relevance of&#xD;
      this population, scientific societies also suggest to propose prospective studies for this&#xD;
      subset of frail patients (European Organization for Research and treatment of cancer (EORTC),&#xD;
      European Society for Medical oncology (ESMO)). In addition, it is necessary to collect data&#xD;
      on specific categories, which are as homogeneous as possible. Therefore, the purpose of this&#xD;
      study is to evaluate efficacy and safety of a tailored RT approach administered with a&#xD;
      curative intent in a subset of frails elderly patients not candidates neither to standard&#xD;
      concurrent RT-CT / RT-cetuximab nor to palliative treatment/best supportive care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2021</start_date>
  <completion_date type="Anticipated">February 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Loco-regional control</measure>
    <time_frame>24 months after the start of treatment</time_frame>
    <description>clinical or radiological (RECIST 1.1) disease progression from end of treatment with tumor present, or to the date of salvage surgery of primary tumor with tumor present performed for clinical or radiological (RECIST 1.1) disease progression, whichever comes first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of severe sub-acute or late toxicity</measure>
    <time_frame>at 6 and 12 months after the completion of radiotherapy</time_frame>
    <description>assessment of toxicity according to CTCAE v5.0 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause-specific mortality rates</measure>
    <time_frame>within 3 months after start of treatment</time_frame>
    <description>Patients who died from cancer/total amount</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>defined as the time from the date of randomization to the date of death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>per modified Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>G8 role</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>correlation between G8 pre-screening evaluation and toxicity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>radiomics</measure>
    <time_frame>through study completion, an average of 5 year</time_frame>
    <description>evaluation of radiomics features in study population: using an automated high-throughput extraction of large amounts of quantitative features</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Open: non elective irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients within inclusion criteria will be enrolled in the experimental treatment: a radiation therapy addressed to non elective site of disease and with a simultaneous integrated boost</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Non elective radiotherapy</intervention_name>
    <description>Simultaneous integrated boost on CTV volumes, delineated as per guidelines, with the exception of intermediate-low risk, where the CTVs are experimental.</description>
    <arm_group_label>Open: non elective irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  locally advanced non-metastatic HNSCC patients older than 70 years&#xD;
&#xD;
          -  Primary tumor clinically and radiologically detectable and measurable (staging&#xD;
             according to ed. TNM VII and also VIII.&#xD;
&#xD;
          -  patients defined by the tumor board (ENT, Oncologist, Radiotherapist, Nutritionist) as&#xD;
             1) not eligibles for RTCT / RT-cetuximab treatment 2) not amenable to radical surgery&#xD;
             and 3) not candidates for treatments with palliative intent/best supportive care&#xD;
&#xD;
          -  Availability of staging with CT/PET for distant metastasis and CT/MRI for primary&#xD;
             tumor&#xD;
&#xD;
          -  Karnofsky performance status (KPS) â‰¥60/100&#xD;
&#xD;
          -  Oropharynx , Hypopharynx and Larynx, Oral cavity: stage III and IV and Unknown&#xD;
             primitive P16-POSITIVE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 70 years&#xD;
&#xD;
               -  Staging exams done 45 days before the date of the beginning of the treatment&#xD;
&#xD;
               -  Subsites: nasopharynx, salivary glands, paranasal sinuses. Metastatic disease&#xD;
&#xD;
               -  Gross total excision&#xD;
&#xD;
               -  All subsites concerned if N3.&#xD;
&#xD;
               -  Squamous cell neoplasms of the glottic larynx T1-T2 N0.&#xD;
&#xD;
               -  Unknown primary HPV negative or EBV positive.&#xD;
&#xD;
               -  Presence of distant metastases or sub-clavicular lymphadenopathies.&#xD;
&#xD;
               -  Previous surgery on T and/or N except diagnostic tonsillectomy.&#xD;
&#xD;
               -  3D-conformational radiotherapy technique&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisa D'Angelo</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedaliero Universitaria Policlinico Modena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pasquale Mighali, MD</last_name>
    <phone>+39 0594225868</phone>
    <email>pasqualemighali@aou.mo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisa D'Angelo, MD</last_name>
    <phone>+39 3934317599</phone>
    <email>dangelo.elisa@aou.mo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AOUPoliclinicoModena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pasquale Mighali</last_name>
      <phone>+39 0594225868</phone>
      <email>pasquale.mighali@aou.mo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero Universitaria Policlinico Modena</investigator_affiliation>
    <investigator_full_name>Elisa D'angelo</investigator_full_name>
    <investigator_title>Medical Doctor, MD</investigator_title>
  </responsible_party>
  <keyword>Elderly</keyword>
  <keyword>Vulnerable</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Non-elective Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

